Kuwashima Y, Kurosumi M, Kobayashi Y, Tanuma J, Suemasu K, Higashi Y, Kasamatsu T, Shiromizu K, Matsuzawa M, Kishi K
Department of Pathology, Saitama Cancer Center, Japan.
Anticancer Res. 1996 Sep-Oct;16(5A):2993-6.
Seven cases of endometrial adenocarcinoma patients who had experienced long-term tamoxifen treatments as adjuvant therapy of breast carcinoma, were investigated with respect to estrogen receptor (ER) status. Four cases of endometrial adenocarcinoma without tamoxifen treatment but with a previous history of breast carcinoma were investigated for comparison. One of the 7 and two of the 4 cases were positive for ER immunohistochemically. Thus, the frequency of ER positivity in secondary endometrial adenocarcinoma seemed to be at random among tamoxifen-treated and non-treated breast cancer patients. These results suggest that tamoxifen-mediated human endometrial carcinogenesis may not involve estrogenic pathway(s) but may involve other carcinogenic mechanisms such as DNA adduct formation as shown in rat liver tumorigenesis.
对7例接受他莫昔芬长期治疗作为乳腺癌辅助治疗的子宫内膜腺癌患者进行了雌激素受体（ER）状态调查。选取4例未接受他莫昔芬治疗但有乳腺癌病史的子宫内膜腺癌患者作为对照。7例中有1例、4例中有2例ER免疫组化呈阳性。因此，在接受他莫昔芬治疗和未接受治疗的乳腺癌患者中，继发性子宫内膜腺癌的ER阳性频率似乎是随机的。这些结果表明，他莫昔芬介导的人类子宫内膜致癌作用可能不涉及雌激素途径，而可能涉及其他致癌机制，如大鼠肝脏肿瘤发生中所示的DNA加合物形成。
